Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.

<h4>Aims</h4>Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sebastian Cremer, Lisa Pilgram, Alexander Berkowitsch, Melanie Stecher, Siegbert Rieg, Mariana Shumliakivska, Denisa Bojkova, Julian Uwe Gabriel Wagner, Galip Servet Aslan, Christoph Spinner, Guillermo Luxán, Frank Hanses, Sebastian Dolff, Christiane Piepel, Clemens Ruppert, Andreas Guenther, Maria Madeleine Rüthrich, Jörg Janne Vehreschild, Kai Wille, Martina Haselberger, Hanno Heuzeroth, Arne Hansen, Thomas Eschenhagen, Jindrich Cinatl, Sandra Ciesek, Stefanie Dimmeler, Stefan Borgmann, Andreas Zeiher, LEOSS study group
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7e234542cdff42628f85dca9a1f5a0e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.

Ejemplares similares